Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Barbara Jost

Allergy & Immunology Saint Louis, MO Medical Doctor

NPI 1144243031 CMS profile 97417

969 N Mason Rd Ste 240, Saint Louis, MO 63141

Open in the dashboard

General payments

$9,431

473 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$460,468 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Barbara Jost of Saint Louis, MO is reported in the CMS Open Payments database as having received $9,431 across 473 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $460,468 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 79th percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,500 74
2024 General $1,549 72
2023 General $1,636 101
2022 General $1,677 102
2021 General $845 52
2020 General $381 25
2019 General $842 47

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Barbara Jost
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to Barbara Jost were reported at $2,500. Among 336 Allergy & Immunology profiles paid that year, the median was $682 and the middle half received between $143 and $2,317.

Show as a table
Year Barbara Jost Allergy & Immunology median Middle half National median
2019 $842 $378 $115–$1,178 $163
2020 $381 $303 $75–$1,581 $114
2021 $845 $407 $122–$1,475 $132
2022 $1,677 $357 $120–$1,340 $149
2023 $1,636 $445 $124–$1,536 $160
2024 $1,549 $541 $129–$1,763 $164
2025 $2,500 $682 $143–$2,317 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $1,512 98 payments
  2. Insmed, Inc. $1,116 10 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $815 55 payments
  4. Genzyme Corporation $730 36 payments
  5. AstraZeneca Pharmaceuticals LP $715 40 payments
  6. Regeneron Healthcare Solutions, Inc. $608 20 payments
  7. Novartis Pharmaceuticals Corporation $373 20 payments
  8. Pfizer Inc. $356 24 payments
  9. CSL Behring $323 11 payments
  10. Grifols USA, LLC $296 14 payments
  11. Other $2,586 145 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,523 463 payments
  2. Travel and Lodging $769 4 payments
  3. Education $74 3 payments
  4. Consulting Fee $65 3 payments
Products named General payments · program years 2019–2025
  1. DUPIXENT Immunology $1,383 70 payments
  2. NUCALA $737 48 payments
  3. TRELEGY ELLIPTA $538 41 payments
  4. DUPIXENT Inflammation And Immunology $500 17 payments
  5. TAKHZYRO $347 14 payments
  6. Hizentra $286 9 payments
  7. Xhance $273 16 payments
  8. RUCONEST $257 11 payments
  9. Xembify $243 11 payments
  10. CUVITRU $242 30 payments
  11. Other $4,951 294 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 104 drugs

Part D claims

5,282

Median for Allergy/ Immunology: 449

Drug cost

$845,355

Median for Allergy/ Immunology: $169,700

Branded share of claims

22.3%

Median for Allergy/ Immunology: 37.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hizentra Immun Glob G(Igg)/Pro/Iga 0-50 Brand 47 $246,136
Nucala Mepolizumab Brand 11 $141,329
Eliquis Apixaban Brand 66 $65,724
Dupixent Syringe Dupilumab Brand 13 $48,453
Januvia Sitagliptin Phosphate Brand 53 $44,080
Ozempic Semaglutide Brand 46 $42,822
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 47 $35,360
Xolair Omalizumab Brand 12 $33,523
Breo Ellipta Fluticasone/Vilanterol Brand 52 $21,975
Rybelsus Semaglutide Brand 13 $15,060

The 10 drugs with the highest cost, of 104 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,579 Part D prescribers listed as Allergy/ Immunology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 44 billing codes

Paid by Medicare

$197,684

Of which drugs: $41,685

Medicare patients

613

Average age 75

Services billed

6,171

441 women, 172 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 72%
Arthritis 51%
Osteoporosis 24%
Diabetes 21%
Depression 21%
Ischemic heart disease 19%
Cancer 17%
Atrial fibrillation 13%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 106 106 $30,538
Vaccine for influenza for injection into muscle 90653 Office 101 101 $8,264
Sarscv2 vac 30mcg trs-suc im 91320 Office 17 17 $2,597
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 17 44 $38

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 24 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $211
  • GENZYME CORPORATION $93
$304 13 —
NUCALA
  • GlaxoSmithKline, LLC. $175
$175 11 —
XOLAIR
  • Novartis Pharmaceuticals Corporation $88
  • Genentech USA, Inc. $66
$154 12 —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $115
$115 — —
TEZSPIRE
  • AstraZeneca Pharmaceuticals LP $59
  • Amgen Inc. $27
$86 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 24 in the dashboard with a free account

Records

473 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy & Immunology in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record